IDH-mut glioma had better OS (p < 0.001) and PFS (p < 0.001) compared with patients without IDH1 mutation (Supplementary Figures 3C, D), which was in agreement with studies reported elsewhere (26, 27). This evidence concerns the gene IDH2 and central nervous system cancer.